Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity

Obesity Research and Clinical Practice

Volumn 12, Issue 1, 2018, Pages 1-8

  Jorge, Antônio Sérgio Barcala ^a   Andrade, João Marcus Oliveira ^a   Paraíso, Alanna Fernandes ^a   Jorge, Gislaine Candida Batista ^a   Silveira, Christine Mendes ^a   de Souza, Ludmilla Regina ^a   Santos, Erivelton Pereira ^a   Guimaraes, André Luiz Sena ^a,b   Santos, Sérgio Henrique Sousa ^a,b   De Paula, Alfredo Maurício Batista ^a  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anthropometric factors; Class III obesity; Non alcoholic fatty liver disease; Proinflammatory cytokines; Real time PCR

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR; AUTACOID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD BIOCHEMISTRY; BODY MASS; CLASS III OBESITY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTRA-ABDOMINAL FAT; LIVER TISSUE; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; OBESITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WHITE ADIPOSE TISSUE; COMPLICATION; GENE EXPRESSION PROFILING; METABOLISM; MIDDLE AGED; MORBID OBESITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; BARIATRIC SURGERY; BIOMARKERS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84964336590     PISSN: 1871403X     EISSN: 18780318     Source Type: Journal    
DOI: 10.1016/j.orcp.2016.03.009     Document Type: Article

References (68)

1. Swinburn, B.A., Sacks, G., Hall, K.D., McPherson, K., Finegood, D.T., Moodie, M.L., et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378 (2011), 804–814.
2. Comuzzie, A.G., Allison, D.B., The search for human obesity genes. Science 280 (1998), 1374–1377.
3. Hill, J.O., Peters, J.C., Environmental contributions to the obesity epidemic. Science 280 (1998), 1371–1374.
4. Prospective Studies Collaboration, Whitlock, G., Lewington, S., Sherliker, P., Clarke, R., Emberson, J., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373 (2009), 1083–1096.
5. Chen, S.H., He, F., Zhou, H.L., Wu, H.R., Xia, C., Li, Y.M., Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis 12 (2011), 125–130.
6. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
7. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
8. Albano, E1, Mottaran, E., Vidali, M., Reale, E., Saksena, S., Occhino, G., et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54 (2005), 987–993.
9. Andersen, T., Christoffersen, P., Gluud, C., The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes 8 (1984), 107–115.
10. Angulo, P., Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology 53 (2011), 1792–1794.
11. Adams, L.A., Sanderson, S., Lindor, K.D., Angulo, P., The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005), 132–138.
12. Paletas, P.P.K., Non alcoholic fatty liver disease two-hit process: multifactorial character of the second hit. Hippokratia, 2009, 13.
13. Schreuder, T.C., Verwer, B.J., van Nieuwkerk, C.M., Mulder, C.J., Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 14 (2008), 2474–2486.
14. Borish, L.C., Steinke, J.W., 2. Cytokines and chemokines. J Allergy Clin Immunol 111 (2003), S460–S475.
15. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature 444 (2006), 860–867.
16. Lumeng, C.N., Saltiel, A.R., Inflammatory links between obesity and metabolic disease. J Clin Invest 121 (2011), 2111–2117.
17. Locksley, R.M., Killeen, N., Lenardo, M.J., The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001), 487–501.
18. Bazzoni, F., Beutler, B., The tumour necrosis factor ligand and receptor families. N Engl J Med 334 (1996), 1717–1725.
19. Akira, S., Hirano, T., Taga, T., Kishimoto, T., Biology of multifunctional cytokines: IL-6 and related molecules (IL 1 and TNF). FASEB J 4 (1990), 2860–2867.
20. Fernando, M.R., Reyes, J.L., Iannuzzi, J., Leung, G., McKay, D.M., The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLOS ONE, 9, 2014, e94188.
21. Papanicolaou, D.A., Wilder, R.L., Manolagas, S.C., Chrousos, G.P., The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128 (1998), 127–137.
22. Adams, L.A., Angulo, P., Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 11 (2007), 25–35 viii.
23. SECURITY C-ICOFAN, Intersectorial strategy for obesity prevention and control: recommendations for Brazilian states and municipalities. 2014, 39.
24. Beaton, G.H., Milner, J., McGuire, V., Feather, T.E., Little, J.A., Source of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. Carbohydrate sources, vitamins, and minerals. Am J Clin Nutr 37 (1983), 986–995.
25. Slimani, N1, Ferrari, P., Ocké M., Welch, A., Boeing, H., Liere, M., et al. Standardization of the 24-hour diet recall calibration method used in the European prospective investigation into cancer and nutrition (EPIC): general concepts and preliminary results. Eur J Clin Nutr 54 (2000), 900–917.
26. Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Network, N.C.R., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in nafld: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
27. Hubscher, S.G., Histological assessment of non-alcoholic fatty liver disease. Histopathology 49 (2006), 450–465.
28. Kleiner, D.E1, Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
29. Day, C.P., From fat to inflammation. Gastroenterology 130 (2006), 207–210.
30. Koda, M., Kawakami, M., Murawaki, Y., Senda, M., The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies. J Gastroenterol 42 (2007), 897–903.
31. Patell, R., Dosi, R., Joshi, H., Sheth, S., Shah, P., Jasdanwala, S., Non-alcoholic fatty liver disease (NAFLD) in obesity. J Clin Diagn Res 8 (2014), 62–66.
32. Qureshi, K., Abrams, G.A., Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13 (2007), 3540–3553.
33. van der Poorten, D1, Milner, K.L., Hui, J., Hodge, A., Trenell, M.I., Kench, J.G., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48 (2008), 449–457.
34. Das, S.K., Balakrishnan, V., Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Indian J Clin Biochem 26 (2011), 202–209.
35. Diehl, A.M., Li, Z.P., Lin, H.Z., Yang, S.Q., Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54 (2005), 303–306.
36. Chu, C.J1, Lu, R.H., Wang, S.S., Chang, F.Y., Wu, S.L., Lu, C.L., et al. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumour necrosis factor-alpha. Hepatogastroenterology 54 (2007), 2099–2102.
37. Good, M., Newell, F.M., Haupt, L.M., Whitehead, J.P., Hutley, L.J., Prins, J.B., TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue – influence of BMI and adipose distribution. Diab Vasc Dis Res 3 (2006), 26–33.
38. Hotamisligil, G.S., Arner, P., Caro, J.F., Atkinson, R.L., Spiegelman, B.M., Increased adipose tissue expression of tumour necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995), 2409–2415.
39. Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumour necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.
40. Kern, P.A., Ranganathan, S., Li, C., Wood, L., Ranganathan, G., Adipose tissue tumour necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280 (2001), E745–E751.
41. Verrijken, A., Francque, S., Mertens, I., Talloen, M., Peiffer, F., Van Gaal, L., Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes 34 (2010), 899–907.
42. Wellen, K.E., Hotamisligil, G.S., Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003), 1785–1788.
43. Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K., Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11 (2011), 85–97.
44. Jarrar, M.H1, Baranova, A., Collantes, R., Ranard, B., Stepanova, M., Bennett, C., et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27 (2008), 412–421.
45. Tilg, H., Moschen, A.R., Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19 (2008), 371–379.
46. Brass, E.P., Vetter, W.H., Interleukin-6, but not tumour necrosis factor-alpha, increases lipogenesis in rat hepatocyte primary cultures. Biochem J 301 (1994), 193–197.
47. Crespo, J1, Cayón, A., Fernández-Gil, P., Hernández-Guerra, M., Mayorga, M., Domínguez-Díez, A., et al. Gene expression of tumour necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001), 1158–1163.
48. Wieckowska, A., Papouchado, B.G., Li, Z., Lopez, R., Zein, N.N., Feldstein, A.E., Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103 (2008), 1372–1379.
49. Grunfeld, C., Feingold, K.R., Tumour necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense. Proc Soc Exp Biol Med 200 (1992), 224–227.
50. Wullaert, A., van Loo, G., Heyninck, K., Beyaert, R., Hepatic tumour necrosis factor signaling and nuclear factor-kappab: effects on liver homeostasis and beyond. Endocr Rev 28 (2007), 365–386.
51. Zhang, W., Kudo, H., Kawai, K., Fujisaka, S., Usui, I., Sugiyama, T., et al. Tumour necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem Biophys Res Commun 391 (2010), 1731–1736.
52. Tomita, K., Tamiya, G., Ando, S., Ohsumi, K., Chiyo, T., Mizutani, A., et al. Tumour necrosis factor alpha signalling through activation of kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55 (2006), 415–424.
53. Manco, M., Marcellini, M., Giannone, G., Nobili, V., Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127 (2007), 954–960.
54. Hu, Z.W., Luo, H.B., Xu, Y.M., Guo, J.W., Deng, X.L., Tong, Y.W., et al. Tumour necrosis factor-alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastro-Enterol Belg 72 (2009), 215–221.
55. Pedersen, B.K., Febbraio, M.A., Point Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 102 (2007), 814–816.
56. Yamaguchi, K., Itoh, Y., Yokomizo, C., Nishimura, T., Niimi, T., Fujii, H., et al. Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice. Lab Invest 90 (2010), 1169–1178.
57. Vozarova, B., Weyer, C., Hanson, K., Tataranni, P.A., Bogardus, C., Pratley, R.E., Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9 (2001), 414–417.
58. Makki, K., Froguel, P., Wolowczuk, I., Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm, 2013, 2013, 139239.
59. Mehta, R., Neupane, A., Wang, L., Goodman, Z., Baranova, A., Younossi, Z.M., Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. BMC Gastroenterol, 14, 2014, 208.
60. Baranova, A., Schlauch, K., Elariny, H., Jarrar, M., Bennett, C., Nugent, C., et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 8 (2007), 1111–1118.
61. Feve, B., Bastard, J.P., The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5 (2009), 305–311.
62. Senn, J.J., Klover, P.J., Nowak, I.A., Mooney, R.A., Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002), 3391–3399.
63. Panagiotakos, D.B., Pitsavos, C., Yannakoulia, M., Chrysohoou, C., Stefanadis, C., The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 183 (2005), 308–315.
64. Ju, D.Y., Choe, Y.G., Cho, Y.K., Shin, D.S., Yoo, S.H., Yim, S.H., et al. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol 19 (2013), 140–147.
65. Pagadala, M.R., McCullough, A.J., Non-alcoholic fatty liver disease and obesity: not all about body mass index. Am J Gastroenterol 107 (2012), 1859–1861.
66. Klop, B., Elte, J.W., Cabezas, M.C., Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5 (2013), 1218–1240.
67. Wong, V.W., Hui, A.Y., Tsang, S.W., Chan, J.L., Tse, A.M., Chan, K.F., et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 4 (2006), 1154–1161.
68. Yu, J., Shen, J., Sun, T.T., Zhang, X., Wong, N., Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 23 (2013), 483–491.